Simone Cenci

Age related diseases

Simone Cenci, Head of Unit

cenci.simone@hsr.it



Our lab studies the biology of normal plasma cells (PC), terminally differentiated effectors of antibody responses, and their malignant counterpart, multiple myeloma (2% of all cancer deaths). We are interested in the role of autophagy in PC ontogenesis and myeloma, in search for new molecular targets and markers of clinical use against PC cancers. Synergic studies on the skeletal microenvironment and bone cells explore the vicious relationship of myeloma with the bone marrow.

Selected Publications

Milan E, Fabbri M, Cenci S. Autophagy in Plasma Cell Ontogeny and Malignancy. J Clin Immunol. 2016 Mar 16. PMID: 26984755 [Epub ahead of print].

Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DL, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell. 2016 May 9. 29(5):639-52.

Klionsky DJ, (…), Cenci S et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016 Jan 2. 12(1):1-222.

Milan E, Perini T, Resnati M, Orfanelli U, Oliva L, Raimondi A, Cascio P, Bachi A, Marcatti M, Ciceri F & Cenci S. A Plastic p62-Dependent Autophagic Reserve Maintains Proteostasis and Determines Proteasome Inhibitor Susceptibility in Multiple Myeloma Cells. Autophagy. 2015 Jul 3;11(7):1161-1178.

Auner, HW & Cenci S. Recent advances and future directions in targeting the secretory apparatus in multiple myeloma. Br J Haematol. 2015 Jan;168(1):14-25.

Cenci S. Autophagy, a new determinant of plasma cell differentiation and antibody responses. Mol Immunol. 2014. http://dx.doi.org/10.1016/j.molimm.2014.02.008. Review.

Oliva L, Cenci S. Autophagy in Plasma Cell Pathophysiology. Front Immunol. 2014. 5:103. eCollection 2014. Review.

Benasciutti E, Mariani E, Oliva L, Scolari M, Perilli E, Barras E, Milan E, Orfanelli U, Fazzalari NL, Campana L, Capobianco A, Otten L, Particelli F, Acha-Orbea H, Baruffaldi F, Faccio R, Sitia R, Reith W and Cenci S. MHC Class II Transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunity. J Bone Min Res. 2014. 29(2):290-303

Pengo N, Scolari M, Oliva L, Milan E, Mainoldi F, Raimondi A, Fagioli C, Merlini A, Mariani E, Pasqualetto E, Orfanelli U, Ponzoni M, Sitia R, Casola S and Cenci S. Plasma cells require autophagy for sustainable immunoglobulin production. Nat Immunol. 2013. 14(3):298-305.

Pengo N and Cenci S. The role of autophagy in plasma cell ontogenesis. Autophagy. 2013. 9(6):942-4.

Cenci S. The proteasome in terminal plasma cell differentiation. Semin Hematol. 2012. 49(39):215–222. Review

Cenci S, Oliva L, Cerruti F, Milan E, Bianchi G, Raule M, Mezghrani A, Pasqualetto E, Sitia R, Cascio P. Pivotal advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors. J Leukoc Biol. 2012. 92(5):921-31.

Cenci S, van Anken E, Sitia R. Proteostenosis and plasma cell pathophysiology. Curr Opin Cell Biol. 2011. 23(2):216-22. Review

Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F, Orsi A, Pasqualetto E, Mezghrani A, Calbi V, Palladini G, Giuliani N, Anderson KC, Sitia R and Cenci S. The proteasome load vs. capacity balance determines apoptoptic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009. 113:3040-3049

Cenci S, Pengo N, Sitia R. Proteotoxic stress and cell lifespan control. Mol Cells. 2008; 26(4):323-8.

Cascio P, Oliva L, Cerruti F, Mariani E, Pasqualetto E, Cenci S* and Sitia R*. Dampening Ab responses using proteasome inhibitors following in vivo B cell activation. Eur J Immunol. 2008. 38:658-667

Cenci S and Sitia R. Managing and exploiting stress in the antibody factory. FEBS Letters. 2007. 581:3652-3657.

Cenci S, Mezghrani A, Cascio P, Cerruti F, Mattioli L, Oliva L, Orsi A, Masciarelli S, Ruffato E, Pasqualetto E, Sitia R. Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J. 2006. 25(5):1104-13

Cenci S, Toraldo G, Weitzmann MN, Roggia C, Gao Y, Qien WP, Sierra O, Pacifici R. Estrogen deficiency causes bone loss by upregulating T cell proliferation and lifespan through IFNγ induced class II transactivator. Proc Natl Acad Sci USA. 2003. 100(18): 10405-10

Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Pacifici R. Estrogen deficiency induces bone loss by enhancing T cell production of TNFα. J Clin Invest. 2000. 106(10):1229-37

Cenci S, Weitzmann MN, Gentile MA, Aisa MC, Pacifici R. M-CSF neutralization and Egr-1 deficiency prevent ovariectomy-induced bone loss. J Clin Invest. 2000. 105(9):1279-1287

Weitzmann MN*, Cenci S*, Rifas L, Brown C, Pacifici R. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood. 2000. 96(5):1873-8.

* Shared first or senior authorship

 Total citations: 2,220; H Index: 18 (Scopus, May 2016)

 

Home | Curriculum | Lab members | Research | Publications